Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer
Corresponding Author
Tobias Ach
Department of Oral and Maxillofacial Surgery, University of Regensburg, Regensburg, Germany
Correspondence: Dr Tobias Ach, Department of Oral and Maxillofacial Surgery, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany. Tel: 0049-941-9446360, Fax: 0049-941-9446342, E-mail: [email protected]Search for more papers by this authorStephan Schwarz-Furlan
Institute of Pathology, Kaufbeuren, Germany
Search for more papers by this authorStephanie Ach
Department of Oral and Maxillofacial Surgery, University of Regensburg, Regensburg, Germany
Search for more papers by this authorAbbas Agaimy
Department of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
Search for more papers by this authorMichael Gerken
Center of Tumor Registry, University of Regensburg, Regensburg, Germany
Search for more papers by this authorChristian Rohrmeier
Department of Otorhinolaryngology, University of Regensburg, Regensburg, Germany
Search for more papers by this authorJohannes Zenk
Department of Otorhinolaryngology, Hospital of Augsburg, Augsburg, Germany
Search for more papers by this authorHeinrich Iro
Department of Otorhinolaryngology, University of Erlangen-Nuremberg, Erlangen, Germany
Search for more papers by this authorGero Brockhoff
Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
Search for more papers by this authorTobias Ettl
Department of Oral and Maxillofacial Surgery, University of Regensburg, Regensburg, Germany
Search for more papers by this authorCorresponding Author
Tobias Ach
Department of Oral and Maxillofacial Surgery, University of Regensburg, Regensburg, Germany
Correspondence: Dr Tobias Ach, Department of Oral and Maxillofacial Surgery, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany. Tel: 0049-941-9446360, Fax: 0049-941-9446342, E-mail: [email protected]Search for more papers by this authorStephan Schwarz-Furlan
Institute of Pathology, Kaufbeuren, Germany
Search for more papers by this authorStephanie Ach
Department of Oral and Maxillofacial Surgery, University of Regensburg, Regensburg, Germany
Search for more papers by this authorAbbas Agaimy
Department of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
Search for more papers by this authorMichael Gerken
Center of Tumor Registry, University of Regensburg, Regensburg, Germany
Search for more papers by this authorChristian Rohrmeier
Department of Otorhinolaryngology, University of Regensburg, Regensburg, Germany
Search for more papers by this authorJohannes Zenk
Department of Otorhinolaryngology, Hospital of Augsburg, Augsburg, Germany
Search for more papers by this authorHeinrich Iro
Department of Otorhinolaryngology, University of Erlangen-Nuremberg, Erlangen, Germany
Search for more papers by this authorGero Brockhoff
Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
Search for more papers by this authorTobias Ettl
Department of Oral and Maxillofacial Surgery, University of Regensburg, Regensburg, Germany
Search for more papers by this authorAbstract
Fibroblast growth factor receptor 1 and 3 (FGFR1, FGFR3) impact on tissue homoeostasis, embryonic development and carcinogenesis. Murine double minute protein 4 (MDM4) and mouse double minute 2 homologue (MDM2) are regulators of p53-protein and may be the origin of an apoptosis overpowering cascade.
A collective of 266 carcinomas of salivary glands were investigated for MDM2, MDM4, FGFR1 and FGFR3 aberrations by fluorescence in situ hybridization (FISH). The results were matched with clinicopathological parameters and with expression of PTEN and p53.
MDM2 gene amplification (n = 9) and chromosomal aberrations (trisomy, n = 47; high polysomy, n = 7) are linked to high-grade malignancy (P < 0.001), lymph node metastasis (P = 0.001), advanced tumour size (P = 0.013) and stage (P < 0.001), gender (P = 0.002) and age (P = 0.001). MDM4 gene amplification (n = 19) and chromosomal aberrations (trisomy, n = 34; high polysomy, n = 31) are correlated to high-grade malignancy (P < 0.001), lymph node metastasis (P = 0.008), advanced tumour size (P = 0.039), stage (P = 0.004) and loss of PTEN (P < 0.001). Only, high-grade malignancy (P < 0.001), lymph node metastasis (P = 0.036) and advanced tumour stage (P = 0.025) are associated with FGFR3 amplification (n = 1) or chromosomal aberrations (low polysomy, n = 61; high polysomy, n = 55) but not with MDM4 alterations.
FGFR1 amplifications (n = 5) and chromosomal aberrations (trisomy, n = 38; high polysomy, n = 30) are associated with high-grade malignancy (P < 0.001), advanced tumour size (P = 0.026) and stage (P = 0.004), gender (P = 0.016) and age (P = 0.023).
Aberrations of MDM2, MDM4, FGFR1 and FGFR3 correlate with aggressive tumour growth and nodal metastasis. MDM2 (P < 0.001), MDM4 (P = 0.005) and FGFR3 (P = 0.006) alterations are associated with worse overall survival of patients with salivary gland cancer.
References
- 1Speight PM, Barrett AW. Salivary gland tumours. Oral Dis 2002; 8: 229–40.
- 2Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008; 53: 567–77.
- 3Ettl T, Stiegler C, Zeitler K, et al. EGFR, HER2, survivin and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 2012; 43: 921–31.
- 4Ach T, Zeitler K, Schwarz-Furlan S, et al. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch 2013; 462: 65–72.
- 5Grünewald I, Vollbrecht C, Meinrath J, et al. Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget 2015; 6: 18224–37.
- 6Keam B, Kim SB, Shin SH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer 2015; 121: 2612–7.
- 7Vairaktaris E, Ragos V, Yapijakis C, et al. FGFR-2 and -3 play an important role in initial stages of oral oncogenesis. Anticancer Res 2006; 26: 4217–22.
- 8Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005; 16: 233–47.
- 9Tomlinson DC, Knowles MA, Speirs V. Mechanism of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 2012; 130: 2857–66.
- 10Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev 2013; 1–21.
- 11Kang S, Dong S, Gu TL. FGFR3 activates RSK2 to mediate hematopoetic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 2007; 12: 201–14.
- 12Henson BJ, Collin SM. Overexpression of KLF13 and FGFR3 in oral cancer cells. Cytogenet Genome Res 2010; 128: 192–8.
- 13Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol 2014; 25: 552–63.
- 14Ettl T, Schwarz-Furlan S, Haubner F, et al. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol 2012; 48: 822–30.
- 15Ettl T, Baader K, Stiegler C, et al. Loss of PTEN is associated with elevated EGFR and HER2 expression adn worse prognosis in salivary gland cancer. Br J Cancer 2012; 106: 719–26.
- 16Marine JC, Jochemsen AG. Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun 2005; 331: 750–60.
- 17Toledo F, Wahl G. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909–23.
- 18Shvarts A, Bazuine M, Dekker P, Ramos YF, Steegenga WT, Merckx G. Isolation and identification of the human homolog of a new p53-binding protein, MDMX. Genomics 2007; 43: 34–42.
- 19Li Q, Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 2013; 19: 34–41.
- 20Valentin-Venga YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 2007; 38: 1553–62.
- 21Markey MP. Regulation of MDM4. Front Biosci 2011; 16: 1144–56.
- 22Wade M, Li YC, Wahl G. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13: 83–96.
- 23Barak Y, Gottlieb E, Juven-Gershon T, Oren M. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444: 61–6.
- 24Philips A. HDMX-L is expressed from a functional p53-responsive promotor in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity. J Biol Chem 2010; 285: 29111–27.
- 25Kato S, Elkin SK, Schwaederle M, et al. Genomic landscape of salivary gland tumos. Oncotarget 2015; 28: 25631–45.
- 26Chiosea SI, Williams L, Griffith CC, et al. Molecular characterization of apocrine salivary duct carcinoma. Am J Surg Pathol 2015; 39: 744–52.
- 27da Cruz Perez DE, de Abreu Alves F, Nobuko Nishimoto I, de Almeida OP, Kowalski LP. Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncol 2006; 42: 139–46.
- 28Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol 2008; 44: 563–70.
- 29Marcinow A, Ozer E, Teknos T, et al. Clinicopathologic predictors of recurrence and overall survival in adenoid cystic carcinoma of the head and neck: a single institutional experience at a tertiary care center. Head Neck 2014; 36: 1705–11.
- 30Luukkaa H, Klemi P, Leivo I, Vahlberg T, Grenman R. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol 2006; 45: 669–75.
- 31Kärjä VJ, Syrijänen KJ, Kurvinen AK, Syrijänen SM. Expression and mutations of p53 in salivary gland tumours. J Oral Pathol Med 1997; 26: 217–23.
- 32Barnes L, Eveson JW, Reichart P. Tumours of the salivary gland. In: Pathology & Genetics, Head and Neck Tumours, ed. World Health Organization Classification of Tumours. Lyon: IARC Press, 2005; 209–81.
- 33Jouzdani E, Yachouh J, Costes V, Faillie JL, Cartier C, Poizat F. Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution. Eur J Cancer 2010; 46: 323–31.
- 34Therkildsen MH, Christensen M, Andersen LJ, Schiodt T, Hansen HS. Salivary gland carcinomas-prognostic factors. Acta Oncol 1998; 37: 701–13.
- 35Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–10.
- 36Schwarz S, Stiegler C, Muller M, et al. Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11;19) translocation. Histopathology 2011; 58: 557–70.
- 37Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643–55.
- 38Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009; 20: 298–304.
- 39Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924–30.
- 40Sircar K, Yoshimoto M, Monzon FA, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009; 218: 505–13.
- 41Yu H, Wang L-E, Liu Z, Wei S, Li G, Sturgis EM. Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck. Pharmacogenet Genomics 2011; 21: 388–96.
- 42Bean J, Brennan C, Shih J. MET amplification occurs with or without T970M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932–7.
- 43Sampieri K, Mencarelli MA, Epistolato MC. Genomic differences between retinoma and retinoblastoma. Acta Oncol 2008; 47: 1483–92.
- 44Nakashima M, Kondo S, Shimizu Y, Wakisaka N, Murono S, Furukawa M. Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma. Acta Otolaryngol 2008; 128: 808–13.
- 45Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res 2004; 2: 1–8.
- 46Mantesso A, Loducca SV, Bendit I, Garicochea B, Nunes FD, de Araujo VC. Mdm2 mRNA expression in salivary gland tumour cell lines. J Oral Pathol Med 2004; 33: 96–101.
- 47De Lima Mde D, Marques YM, Alves SDE M Jr, et al. MDM2, P53, P21WAF1 and pAKT protein levels in genesis and behaviour of adenoid cystic carcinoma. Cancer Epidemiol 2009; 33: 142–6.
- 48Mancini F, Moretti F. Mitochondrial MDM4 (MDMX) – an unpredicted role in the p53-mediated intrinsic apoptotic pathway. Cell Cycle 2009; 8: 3854–9.
- 49Rowley H. The molecular genetics of head and neck cancer. J Laryngol Otol 1998; 112: 607–12.
- 50Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307–10.
- 51Xiong S. Mouse models of Mdm2 and Mdm4. Chin J Cancer 2013; 7: 371–5.
- 52Momand J, Zambetti G, Oslon D, George DC, Levine AJ. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–45.
- 53Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13: 927–34.
- 54Ettl T, Schwarz S, Kühnel T, Stockmann P, Reichert TE, Driemel O. Prognostic value of immunohistochemistry in salivary gland cancer. HNO 2008; 56: 231–8.
- 55Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. Int J Cancer 1998; 79: 263–8.
10.1002/(SICI)1097-0215(19980619)79:3<263::AID-IJC9>3.0.CO;2-N CAS PubMed Web of Science® Google Scholar
- 56Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002; 277: 5484–9.
- 57Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340–4.
- 58Gembarska A, Luciani F, Fedele C, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 2012; 18: 1239–47.
- 59Secchiero P, Zerbinati C, Melloni E, et al. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia 2007; 9: 853–61.
- 60Graves B, Thompson T, Xia M, Janson C, Lukacs C, Deo D. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci USA 2012; 109: 11788–93.
- 61Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev 2014; 34: 280–300.
- 62Ho AS, Kaunam K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013; 45: 791–8.
- 63Baldin V, Roman A, Bosc-Bierne I, Almalric F, Bouche G. Translocation of bFGF to the nucleus is G1 phase cell cycle specific in bovine aortic endothelial cells. EMBO J 1990; 9: 1511–7.
- 64Myoken Y, Myoken Y, Okamoto T, Sato JD, Kan M, McKeehan WL. Immunohistochemical localization of fibroblast growth factor-1 (FGF-1), FGF-2 and fibroblast growth factor receptor-1 (FGFR-1) in human malignant salivary gland tumors. J Oral Pathol 1996; 178: 429–36.
10.1002/(SICI)1096-9896(199604)178:4<429::AID-PATH495>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
- 65Yu Z, Biro S, Fu Y. Localization of basic fibroblast growth factor in bovine endothelial cells: immunohistochemical and biochemical studies. Exp Cell Res 1993; 204: 247–59.
- 66Furuse C, Miguita L, Garcia Rosa AC, et al. Study of growth factors and receptors in carcinoma ex pleomorphic adenoma. J Oral Pathol Med 2010; 39: 540–7.
- 67Huang YQ, Li YD, Li GK, Jin Z, Ma J. The evaluation of basic fibroblast growth factor and fibroblastic growth factor receptor 1 levels in saliva and serum of patients with salivary gland tumor. DNA Cell Biol 2012; 31: 520–3.
- 68Zhang Y, Hiraishi Y, Wang H, Sumi KS, Hayashido Y, Toratani S. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer 2005; 117: 166–8.
- 69McLeskey SW, Kurebayashi J, Honig SF, et al. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res 1993; 53: 2168–77.
- 70Ishigami T, Uzawa K, Higo M, Nomura H, Satio K. Genes and molecular pathways related to radioresistance of oral squamous cell carcinoma cells. Int J Cancer 2007; 120: 2262–70.
- 71Qiu H, Yashiro M, Zhang X, Miwa A, Hirakawa K. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. Cancer Lett 2011; 307: 47–52.
- 72Yashiro M, Shinto O, Nakamura K, et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil in scirrhous gastric carcinoma. Int J Cancer 2010; 126: 1004–16.
- 73Dillon PM, Chakraberty S, Moskaluk CA, Joshi PJ, Thomas CY. Adenoid cystic carcinoma: a review of recent advances, molecular targets and clinical trials. Head Neck 2016; 38: 620–7.
- 74Moskaluk CA, Baras AS, Mancuso SA, et al. Development and characterization of xenograft model systems for adenoid cystic carcinoma. Lab Invest 2011; 91: 1480–90.
